Mathieu Lesouhaitier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mathieu Lesouhaitier has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Arnaud Gacouin
Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital , 2 rue Henri Le Guilloux, 35033 Rennes
2 shared publicationsC. Vigneau
Service de néphrologie, CHU Rennes, Rennes, France
2 shared publicationsCécile Vigneau
Division of Nephrology, CHU Rennes, Rennes, France
2 shared publicationsJean-Marc Tadié
University Hospital of Rennes
2 shared publications- Jean-Marc Tadié
Médecine Intensive-Réanimation, Hôpital Pontchaillou, Institut National de la Santé et de la Recherche Médicale, Établissement Français du Sang Bretagne, Université de Rennes, UMR U1236
2 shared publications - Vincent Cattoir
CHU de Rennes, Service de Bactériologie-Hygiène Hospitalière, Rennes, France
2 shared publications
Latest Publications
- 22 April 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Integrated or Parallel Configurations for Renal Replacement Therapy in Patients on VenoArterial Extracorporeal Membrane Oxygenation, a Single Center Retrospective Study
Background: Acute kidney injury (AKI) is frequent in patients supported with venoarterial extracorporeal membrane oxygenation (VA-ECMO), largely due to the severity of cardiogenic shock and multiorgan failure. Renal replacement therapy (RRT) can be delivered either via an indwelling catheter (parallel system, PS) or through direct connection to the ECMO circuit (integrated system, IS). Their respective safety profiles, particularly regarding infectious, hemorrhagic, and circuit-related complications, remain insufficiently characterized. Methods: We conducted a single-center retrospective analysis of prospectively collected data from consecutive adults who received RRT for ≥24 h while on VA-ECMO between 2006 and 2019. Complications occurring during the concomitant ECMO–RRT period were compared between IS and PS configurations. Results: Eighty patients (84 procedures: 42 IS, 42 PS) were included. Infectious complications occurred in 31% of IS procedures and 45.2% of PS procedures, with earlier onset in the PS group (3 vs 5 days; p = 0.048). However, in multivariable analysis, IS was not independently associated with reduced infection risk (OR 0.67 [0.27-1.70]; p = 0.421). Hemorrhagic events (54.8% IS vs 59.5% PS) and circuit dysfunctions, including filter clotting, were comparable between groups. Conclusion: In VA-ECMO patients requiring RRT, integrated and parallel configurations demonstrate similar safety profiles with no significant differences in infectious, hemorrhagic, or circuit-related complications. These findings support selecting the RRT configuration based primarily on local expertise and technical feasibility rather than expected differences in complication risk
- 22 April 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Integrated or Parallel Configurations for Renal Replacement Therapy in Patients on VenoArterial Extracorporeal Membrane Oxygenation, a Single Center Retrospective Study
Background: Acute kidney injury (AKI) is frequent in patients supported with venoarterial extracorporeal membrane oxygenation (VA-ECMO), largely due to the severity of cardiogenic shock and multiorgan failure. Renal replacement therapy (RRT) can be delivered either via an indwelling catheter (parallel system, PS) or through direct connection to the ECMO circuit (integrated system, IS). Their respective safety profiles, particularly regarding infectious, hemorrhagic, and circuit-related complications, remain insufficiently characterized. Methods: We conducted a single-center retrospective analysis of prospectively collected data from consecutive adults who received RRT for ≥24 h while on VA-ECMO between 2006 and 2019. Complications occurring during the concomitant ECMO–RRT period were compared between IS and PS configurations. Results: Eighty patients (84 procedures: 42 IS, 42 PS) were included. Infectious complications occurred in 31% of IS procedures and 45.2% of PS procedures, with earlier onset in the PS group (3 vs 5 days; p = 0.048). However, in multivariable analysis, IS was not independently associated with reduced infection risk (OR 0.67 [0.27-1.70]; p = 0.421). Hemorrhagic events (54.8% IS vs 59.5% PS) and circuit dysfunctions, including filter clotting, were comparable between groups. Conclusion: In VA-ECMO patients requiring RRT, integrated and parallel configurations demonstrate similar safety profiles with no significant differences in infectious, hemorrhagic, or circuit-related complications. These findings support selecting the RRT configuration based primarily on local expertise and technical feasibility rather than expected differences in complication risk
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude des dysfonctions immunologiques induites par la circulation extracorporelle
La circulation extracorporelle (CEC) utilisé en chirurgie cardiaque ou en réanimation pour la prise en charge d’un choc cardiogénique (ECMO) est associé à la survenue d’infections nosocomiales assombrissant le pronostic des patients. Ces infections sont l’expression de dysfonctions immunitaires induites par la CEC. La première partie de notre travail s’est attaché à décrire les modifications phénotypiques des différentes populations immunitaires induites par l’ECMO. Nous avons pu mettre en évidence que cette CEC induisait un recrutement de polynucléaires neutrophiles (PMN) immatures et une anergie lymphocytaire caractérisée par une apoptose marquée ainsi qu’une diminution des capacités de prolifération. Nous avons poursuivi notre travail par l’étude exhaustive des PMN au cours de la chirurgie cardiaque avec CEC. Cette technique induit le recrutement de PMN matures aux fonctions de bactéricidie intactes n’expliquant donc pas la susceptibilité des patients aux infections post-opératoires. Finalement, comme l’ECMO, la CEC de chirurgie cardiaque induit une augmentation de l’apoptose lymphocytaire ainsi qu’une diminution des capacités de prolifération. Ces anomalies sont associées au recrutement de cellules immunosuppressives, les Myeloïd Derived Supressor Cells qui, via leur activité arginase, entraine une diminution de la disponibilité en arginine. Cet acide aminé est indispensable aux fonctions lymphocytaires et notre connaissance du métabolisme de l’arginine au décours des état inflammatoires sévères nous a permis de montrer que la supplémentation en citrulline permet de corriger plus efficacement l’hypoargininémie. La supplémentation en citrulline laisse entrevoir de nouvelles perspectives thérapeutiques afin de limiter les conséquences des phénomènes immunosuppresseurs induits par la CEC.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude des dysfonctions immunologiques induites par la circulation extracorporelle
La circulation extracorporelle (CEC) utilisé en chirurgie cardiaque ou en réanimation pour la prise en charge d’un choc cardiogénique (ECMO) est associé à la survenue d’infections nosocomiales assombrissant le pronostic des patients. Ces infections sont l’expression de dysfonctions immunitaires induites par la CEC. La première partie de notre travail s’est attaché à décrire les modifications phénotypiques des différentes populations immunitaires induites par l’ECMO. Nous avons pu mettre en évidence que cette CEC induisait un recrutement de polynucléaires neutrophiles (PMN) immatures et une anergie lymphocytaire caractérisée par une apoptose marquée ainsi qu’une diminution des capacités de prolifération. Nous avons poursuivi notre travail par l’étude exhaustive des PMN au cours de la chirurgie cardiaque avec CEC. Cette technique induit le recrutement de PMN matures aux fonctions de bactéricidie intactes n’expliquant donc pas la susceptibilité des patients aux infections post-opératoires. Finalement, comme l’ECMO, la CEC de chirurgie cardiaque induit une augmentation de l’apoptose lymphocytaire ainsi qu’une diminution des capacités de prolifération. Ces anomalies sont associées au recrutement de cellules immunosuppressives, les Myeloïd Derived Supressor Cells qui, via leur activité arginase, entraine une diminution de la disponibilité en arginine. Cet acide aminé est indispensable aux fonctions lymphocytaires et notre connaissance du métabolisme de l’arginine au décours des état inflammatoires sévères nous a permis de montrer que la supplémentation en citrulline permet de corriger plus efficacement l’hypoargininémie. La supplémentation en citrulline laisse entrevoir de nouvelles perspectives thérapeutiques afin de limiter les conséquences des phénomènes immunosuppresseurs induits par la CEC.
- 12 September 2024
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (1)
Neutrophil phenotype, effector functions, and microbicidal activity in patients with SARS-CoV-2-associated ARDS
Critically ill patients admitted to the intensive care unit (ICU) for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) are at increased risk of bacterial and fungal secondary pulmonary infections due to acquired immune dysfunction. Given that the activity of neutrophils has not been described in these patients, we aimed to investigate the function of neutrophils at ICU admission and on day 7 (D7) postadmission. Neutrophil maturation and several functional indicators were investigated. We detected a significant decrease in reactive oxygen species production at D7, but we did not observe any other significant alterations in neutrophil function. Furthermore, bronchoalveolar lavage obtained from patients displayed no inhibitory effect on the function of neutrophils from healthy donors. These findings indicate that patients admitted to the ICU for SARS-CoV-2-induced ARDS do not acquire neutrophil dysfunction within the first week of their stay, which suggests that nosocomial infections among these patients are not due to acquired neutrophil dysfunctions.
- 12 September 2024
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 117 (1)
Neutrophil phenotype, effector functions, and microbicidal activity in patients with SARS-CoV-2-associated ARDS
Critically ill patients admitted to the intensive care unit (ICU) for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) are at increased risk of bacterial and fungal secondary pulmonary infections due to acquired immune dysfunction. Given that the activity of neutrophils has not been described in these patients, we aimed to investigate the function of neutrophils at ICU admission and on day 7 (D7) postadmission. Neutrophil maturation and several functional indicators were investigated. We detected a significant decrease in reactive oxygen species production at D7, but we did not observe any other significant alterations in neutrophil function. Furthermore, bronchoalveolar lavage obtained from patients displayed no inhibitory effect on the function of neutrophils from healthy donors. These findings indicate that patients admitted to the ICU for SARS-CoV-2-induced ARDS do not acquire neutrophil dysfunction within the first week of their stay, which suggests that nosocomial infections among these patients are not due to acquired neutrophil dysfunctions.
- Open Access
- 10 September 2024
- Published by Springer Nature in Critical Care
- Vol. 28 (1) , 1-15
Cardiopulmonary bypass and VA-ECMO induced immune dysfunction: common features and differences, a narrative review
Cardiopulmonary bypass (CPB) and veno-arterial extracorporeal membrane oxygenation are critical tools in contemporary cardiac surgery and intensive care, respectively. While these techniques share similar components, their application contexts differ, leading to distinct immune dysfunctions which could explain the higher incidence of nosocomial infections among ECMO patients compared to those undergoing CPB. This review explores the immune modifications induced by these techniques, comparing their similarities and differences, and discussing potential treatments to restore immune function and prevent infections. The immune response to CPB and ECMO involves both humoral and cellular components. The kinin system, complement system, and coagulation cascade are rapidly activated upon blood contact with the circuit surfaces, leading to the release of pro-inflammatory mediators. Ischemia–reperfusion injury and the release of damage-associated molecular patterns further exacerbate the inflammatory response. Cellular responses involve platelets, neutrophils, monocytes, dendritic cells, B and T lymphocytes, and myeloid-derived suppressor cells, all of which undergo phenotypic and functional alterations, contributing to immunoparesis. Strategies to mitigate immune dysfunctions include reducing the inflammatory response during CPB/ECMO and enhancing immune functions. Approaches such as off-pump surgery, corticosteroids, complement inhibitors, leukocyte-depleting filters, and mechanical ventilation during CPB have shown varying degrees of success in clinical trials. Immunonutrition, particularly arginine supplementation, has also been explored with mixed results. These strategies aim to balance the inflammatory response and support immune function, potentially reducing infection rates and improving outcomes. In conclusion, both CPB and ECMO trigger significant immune alterations that increase susceptibility to nosocomial infections. Addressing these immune dysfunctions through targeted interventions is essential to improving patient outcomes in cardiac surgery and critical care settings. Future research should focus on refining these strategies and developing new approaches to better manage the immune response in patients undergoing CPB and ECMO. Although often considered similar, CPB and ECMO have distinct immune repercussions. Numerous immunomodulatory strategies have been tested in cardiac surgery patients undergoing CPB to mitigate the induced immunoparesis, but no clinical trials have been conducted for patients on ECMO. C5aR (complement component 5a receptor), CPB (cardiopulmonary bypass), DC (dendritic cells), ECMO (extracorporeal membrane oxygenation), HLA-DR (human leukocyte antigen-DR isotype), NETs (neutrophil extracellular traps), PD-1 (program cell death protein 1), ROS (reactive oxygen species), TLR (toll-like receptor). Created with BioRender.com
- 10 September 2024
- Published by Springer Nature in Critical Care
- Vol. 28 (1) , 1-15
Open AccessCardiopulmonary bypass and VA-ECMO induced immune dysfunction: common features and differences, a narrative review
Cardiopulmonary bypass (CPB) and veno-arterial extracorporeal membrane oxygenation are critical tools in contemporary cardiac surgery and intensive care, respectively. While these techniques share similar components, their application contexts differ, leading to distinct immune dysfunctions which could explain the higher incidence of nosocomial infections among ECMO patients compared to those undergoing CPB. This review explores the immune modifications induced by these techniques, comparing their similarities and differences, and discussing potential treatments to restore immune function and prevent infections. The immune response to CPB and ECMO involves both humoral and cellular components. The kinin system, complement system, and coagulation cascade are rapidly activated upon blood contact with the circuit surfaces, leading to the release of pro-inflammatory mediators. Ischemia–reperfusion injury and the release of damage-associated molecular patterns further exacerbate the inflammatory response. Cellular responses involve platelets, neutrophils, monocytes, dendritic cells, B and T lymphocytes, and myeloid-derived suppressor cells, all of which undergo phenotypic and functional alterations, contributing to immunoparesis. Strategies to mitigate immune dysfunctions include reducing the inflammatory response during CPB/ECMO and enhancing immune functions. Approaches such as off-pump surgery, corticosteroids, complement inhibitors, leukocyte-depleting filters, and mechanical ventilation during CPB have shown varying degrees of success in clinical trials. Immunonutrition, particularly arginine supplementation, has also been explored with mixed results. These strategies aim to balance the inflammatory response and support immune function, potentially reducing infection rates and improving outcomes. In conclusion, both CPB and ECMO trigger significant immune alterations that increase susceptibility to nosocomial infections. Addressing these immune dysfunctions through targeted interventions is essential to improving patient outcomes in cardiac surgery and critical care settings. Future research should focus on refining these strategies and developing new approaches to better manage the immune response in patients undergoing CPB and ECMO. Although often considered similar, CPB and ECMO have distinct immune repercussions. Numerous immunomodulatory strategies have been tested in cardiac surgery patients undergoing CPB to mitigate the induced immunoparesis, but no clinical trials have been conducted for patients on ECMO. C5aR (complement component 5a receptor), CPB (cardiopulmonary bypass), DC (dendritic cells), ECMO (extracorporeal membrane oxygenation), HLA-DR (human leukocyte antigen-DR isotype), NETs (neutrophil extracellular traps), PD-1 (program cell death protein 1), ROS (reactive oxygen species), TLR (toll-like receptor). Created with BioRender.com
- Open Access
- 12 April 2022
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 22 (1) , 1
Correction to: Cerebral nocardiosis in a patient treated with pembrolizumab: a first case report
- 12 April 2022
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 22 (1) , 1
Open AccessCorrection to: Cerebral nocardiosis in a patient treated with pembrolizumab: a first case report
- Open Access
- 16 February 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (8)
Beneficial effects of citrulline enteral administration on sepsis-induced T cell mitochondrial dysfunction
Severe sepsis induces a sustained immune dysfunction associated with poor clinical behavior. In particular, lymphopenia along with increased lymphocyte apoptosis and decreased lymphocyte proliferation, enhanced circulating regulatory T cells (Treg), and the emergence of myeloid-derived suppressor cells (MDSCs) have all been associated with persistent organ dysfunction, secondary infections, and late mortality. The mechanisms involved in MDSC-mediated T cell dysfunction during sepsis share some features with those described in malignancies such as arginine deprivation. We hypothesized that increasing arginine availability would restore T cell function and decrease sepsis-induced immunosuppression. Using a mouse model of sepsis based on cecal ligation and puncture and secondary pneumonia triggered by methicillin-resistant Staphylococcus aureus inoculation, we demonstrated that citrulline administration was more efficient than arginine in increasing arginine plasma levels and restoring T cell mitochondrial function and proliferation while reducing sepsis-induced Treg and MDSC expansion. Because there is no specific therapeutic strategy to restore immune function after sepsis, we believe that our study provides evidence for developing citrulline-based clinical studies in sepsis. Significance Since sepsis induces a sustained immunosuppression responsible for secondary infections acquisition and late mortality, restoring immune function would result in a better outcome. Given the role of arginine deficiency in T cell dysfunction, the evaluation of restoring arginine availability in sepsis has to be explored. Using an animal model of sepsis, we demonstrated that increasing arginine availability enhanced mitochondrial T cell function and decreased sepsis-induced immunosuppression.
- 16 February 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (8)
Open AccessBeneficial effects of citrulline enteral administration on sepsis-induced T cell mitochondrial dysfunction
Severe sepsis induces a sustained immune dysfunction associated with poor clinical behavior. In particular, lymphopenia along with increased lymphocyte apoptosis and decreased lymphocyte proliferation, enhanced circulating regulatory T cells (Treg), and the emergence of myeloid-derived suppressor cells (MDSCs) have all been associated with persistent organ dysfunction, secondary infections, and late mortality. The mechanisms involved in MDSC-mediated T cell dysfunction during sepsis share some features with those described in malignancies such as arginine deprivation. We hypothesized that increasing arginine availability would restore T cell function and decrease sepsis-induced immunosuppression. Using a mouse model of sepsis based on cecal ligation and puncture and secondary pneumonia triggered by methicillin-resistant Staphylococcus aureus inoculation, we demonstrated that citrulline administration was more efficient than arginine in increasing arginine plasma levels and restoring T cell mitochondrial function and proliferation while reducing sepsis-induced Treg and MDSC expansion. Because there is no specific therapeutic strategy to restore immune function after sepsis, we believe that our study provides evidence for developing citrulline-based clinical studies in sepsis. Significance Since sepsis induces a sustained immunosuppression responsible for secondary infections acquisition and late mortality, restoring immune function would result in a better outcome. Given the role of arginine deficiency in T cell dysfunction, the evaluation of restoring arginine availability in sepsis has to be explored. Using an animal model of sepsis, we demonstrated that increasing arginine availability enhanced mitochondrial T cell function and decreased sepsis-induced immunosuppression.
- 11 September 2018
- Published by JLE in Nephrologie & Therapeutique
- Vol. 14 (5) , 414-415
Utilisation des inhibiteurs de checkpoints chez les greffés rénaux
Introduction: Les Inhibiteurs de checkpoints (ICP) ont révolutionné le traitement de plusieurs cancers (mélanome, lymphomes, cancer pulmonaire). Cependant, les essais cliniques ayant conduit à leur utilisation en pratique clinique ont toujours exclu les patients greffés d’organe solide devant le risque de rejet. Néanmoins, les patients greffés ont un risque accru de développer un cancer à cause des traitements immunosuppresseurs et des infections à virus oncogènes. Il existe quelques cas cliniques d’utilisation des ICP chez les patients greffés rénaux avec un taux de rejet bas (4 patients sur 9) [1]. Devant le potentiel biais de publication des cas cliniques, nous avons recensé l’ensemble des patients greffés rénaux traités par ICP en France et en Belgique afin de d’évaluer les effets des ICP chez cette population. Patients/Matériels et méthodes Ont été inclus les patients greffés rénaux traité par ICP avec une survie du patient et/ou du greffon d’au moins 8 jours après le début du traitement. Les centres de transplantation rénale ont été contactés pour recenser les différents cas et le CRF a été rempli par le néphrologue et/ou l’oncologue référent. Observation/Résultats Nous avons identifié 7 patients en France et en Belgique. Ces patients ont été traité par un anticorps anti-CTLA4 (n = 1) ou anti-PD1/PD-L1 (n = 6) pour un mélanome (n = 4), un carcinome pulmonaire (n = 2) ou un carcinome à cellules de Merckel (n = 1). Après l’utilisation du ICP, 3 patients ont présenté un rejet, en moyenne 2 mois après la première utilisation. Tous ces rejets ont été traités par bolus de corticoïdes et arrêt de l’ICP, 2 patients ont finalement perdu leur greffon avec retour en dialyse. Tous les patients n’ayant pas fait de rejet (n = 4) avaient une corticothérapie au moment de l’utilisation du ICP contrairement aux autres. Finalement, la réponse oncologique est faible (n = 1) et 5 patients sont décédés de la progression tumorale. Discussion: Notre série est la première concernant l’utilisation des ICP chez les greffés rénaux. Le taux de rejet est assez bas (43 %) avec un possible effet protecteur de la corticothérapie. En associant les observations de notre série avec les autres cas cliniques publiés, on observe qu’aucun patient traité par un anti-CTLA4 n’a présenté de rejet (n = 4) contrairement aux patients (58 %, n = 7/12) traité par un anti-PD1/PD-L (seul ou en association à un anti-CTLA4). Conclusion: Des registres prospectifs et/ou des études cliniques sont nécessaires afin d’évaluer le rapport bénéfice/risque de l’utilisation des ICP chez ces patients.
- 11 September 2018
- Published by JLE in Nephrologie & Therapeutique
- Vol. 14 (5) , 414-415
Utilisation des inhibiteurs de checkpoints chez les greffés rénaux
Introduction: Les Inhibiteurs de checkpoints (ICP) ont révolutionné le traitement de plusieurs cancers (mélanome, lymphomes, cancer pulmonaire). Cependant, les essais cliniques ayant conduit à leur utilisation en pratique clinique ont toujours exclu les patients greffés d’organe solide devant le risque de rejet. Néanmoins, les patients greffés ont un risque accru de développer un cancer à cause des traitements immunosuppresseurs et des infections à virus oncogènes. Il existe quelques cas cliniques d’utilisation des ICP chez les patients greffés rénaux avec un taux de rejet bas (4 patients sur 9) [1]. Devant le potentiel biais de publication des cas cliniques, nous avons recensé l’ensemble des patients greffés rénaux traités par ICP en France et en Belgique afin de d’évaluer les effets des ICP chez cette population. Patients/Matériels et méthodes Ont été inclus les patients greffés rénaux traité par ICP avec une survie du patient et/ou du greffon d’au moins 8 jours après le début du traitement. Les centres de transplantation rénale ont été contactés pour recenser les différents cas et le CRF a été rempli par le néphrologue et/ou l’oncologue référent. Observation/Résultats Nous avons identifié 7 patients en France et en Belgique. Ces patients ont été traité par un anticorps anti-CTLA4 (n = 1) ou anti-PD1/PD-L1 (n = 6) pour un mélanome (n = 4), un carcinome pulmonaire (n = 2) ou un carcinome à cellules de Merckel (n = 1). Après l’utilisation du ICP, 3 patients ont présenté un rejet, en moyenne 2 mois après la première utilisation. Tous ces rejets ont été traités par bolus de corticoïdes et arrêt de l’ICP, 2 patients ont finalement perdu leur greffon avec retour en dialyse. Tous les patients n’ayant pas fait de rejet (n = 4) avaient une corticothérapie au moment de l’utilisation du ICP contrairement aux autres. Finalement, la réponse oncologique est faible (n = 1) et 5 patients sont décédés de la progression tumorale. Discussion: Notre série est la première concernant l’utilisation des ICP chez les greffés rénaux. Le taux de rejet est assez bas (43 %) avec un possible effet protecteur de la corticothérapie. En associant les observations de notre série avec les autres cas cliniques publiés, on observe qu’aucun patient traité par un anti-CTLA4 n’a présenté de rejet (n = 4) contrairement aux patients (58 %, n = 7/12) traité par un anti-PD1/PD-L (seul ou en association à un anti-CTLA4). Conclusion: Des registres prospectifs et/ou des études cliniques sont nécessaires afin d’évaluer le rapport bénéfice/risque de l’utilisation des ICP chez ces patients.
- 19 July 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (9) , e13355
Impact of donor coronary angiography on kidney transplantation outcomes
Coronary angiography (CA) is the gold standard evaluation of coronary artery disease in potential multi‐organ donors. This use of iodinated contrast media could lead to contrast‐induced acute kidney injury and consequently to delayed graft function (DGF). All patients in France who received a kidney from a 45‐70‐year‐old donor without medical contraindication for cardiac donation and with at least one cardiovascular risk factor were included. Recipients of preemptive kidney transplant or multi‐organ transplant, or who died within the first 8 days post‐transplantation were excluded. Data were obtained from CRISTAL database. From March 2012 to June 2014, 892 kidneys from 483 donors were transplanted. DGF was reported in 38.9% of the 375 kidney recipients grafted with a kidney from the 217 donors who had CA and in 45.5% of the 440 kidney recipients who received a kidney from the 257 donors without CA. Multivariate analysis showed that CA or repeated injection of iodinated contrast media did not influence the risk of DGF. CA did not increase the risk of primary non‐function, the duration of DGF or post‐transplantation hospital stay and did not affect the graft function at 1 year. Evaluation of potential multi‐organ donors with CA does not affect kidney graft outcomes.
- 19 July 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (9) , e13355
Impact of donor coronary angiography on kidney transplantation outcomes
Coronary angiography (CA) is the gold standard evaluation of coronary artery disease in potential multi‐organ donors. This use of iodinated contrast media could lead to contrast‐induced acute kidney injury and consequently to delayed graft function (DGF). All patients in France who received a kidney from a 45‐70‐year‐old donor without medical contraindication for cardiac donation and with at least one cardiovascular risk factor were included. Recipients of preemptive kidney transplant or multi‐organ transplant, or who died within the first 8 days post‐transplantation were excluded. Data were obtained from CRISTAL database. From March 2012 to June 2014, 892 kidneys from 483 donors were transplanted. DGF was reported in 38.9% of the 375 kidney recipients grafted with a kidney from the 217 donors who had CA and in 45.5% of the 440 kidney recipients who received a kidney from the 257 donors without CA. Multivariate analysis showed that CA or repeated injection of iodinated contrast media did not influence the risk of DGF. CA did not increase the risk of primary non‐function, the duration of DGF or post‐transplantation hospital stay and did not affect the graft function at 1 year. Evaluation of potential multi‐organ donors with CA does not affect kidney graft outcomes.
- 1 June 2018
- Published by Elsevier in European Journal of Cancer
- Vol. 96, 111-114
Checkpoint blockade after kidney transplantation
- 1 June 2018
- Published by Elsevier in European Journal of Cancer
- Vol. 96, 111-114
Checkpoint blockade after kidney transplantation